Monocyte CD169 expression in COVID-19 patients upon intensive care unit admission.
Adult
Aged
Biomarkers
/ blood
COVID-19
/ blood
Female
Flow Cytometry
Host-Pathogen Interactions
Humans
Intensive Care Units
Male
Middle Aged
Monocytes
/ immunology
Patient Admission
Predictive Value of Tests
Preliminary Data
Prognosis
Prospective Studies
SARS-CoV-2
/ immunology
Sialic Acid Binding Ig-like Lectin 1
/ blood
Up-Regulation
CD169
COVID-19
monocyte
sepsis
Journal
Cytometry. Part A : the journal of the International Society for Analytical Cytology
ISSN: 1552-4930
Titre abrégé: Cytometry A
Pays: United States
ID NLM: 101235694
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
07
01
2021
received:
22
12
2020
accepted:
08
01
2021
pubmed:
7
2
2021
medline:
18
5
2021
entrez:
6
2
2021
Statut:
ppublish
Résumé
During the second surge of COVID-19 in France (fall 2020), we assessed the expression of monocyte CD169 (i.e., Siglec-1, one of the numerous IFN-stimulated genes) upon admission to intensive care units of 45 patients with RT-PCR-confirmed SARS-CoV2 pulmonary infection. Overall, CD169 expression was strongly induced on circulating monocytes of COVID-19 patients compared with healthy donors and patients with bacterial sepsis. Beyond its contribution at the emergency department, CD169 testing may be also helpful for patients' triage at the ICU to rapidly reinforce suspicion of COVID-19 etiology in patients with acute respiratory failure awaiting for PCR results for definitive diagnosis.
Identifiants
pubmed: 33547747
doi: 10.1002/cyto.a.24315
pmc: PMC8014094
doi:
Substances chimiques
Biomarkers
0
SIGLEC1 protein, human
0
Sialic Acid Binding Ig-like Lectin 1
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
466-471Subventions
Organisme : All authors are supported by Hospices Civils de Lyon and Claude Bernard Lyon-1 University.
Informations de copyright
© 2021 International Society for Advancement of Cytometry.
Références
Cytokine. 2019 Jan;113:446-452
pubmed: 30413290
Nat Rev Immunol. 2020 Jul;20(7):397-398
pubmed: 32457522
J Immunol Methods. 2019 Jul;470:59-63
pubmed: 31082373
Intensive Care Med. 2020 Sep;46(9):1764-1765
pubmed: 32488343
Future Microbiol. 2020 Feb;15:189-201
pubmed: 32065550
Cell. 2020 Sep 17;182(6):1401-1418.e18
pubmed: 32810439
Nat Rev Immunol. 2015 Jul;15(7):429-40
pubmed: 26052098
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
Annu Rev Immunol. 2014;32:513-45
pubmed: 24555472
J Infect Dis. 2021 Feb 24;223(4):562-567
pubmed: 33206973
PLoS Pathog. 2020 Jul 29;16(7):e1008737
pubmed: 32726355
Cytometry A. 2021 May;99(5):466-471
pubmed: 33547747
Crit Care. 2020 Apr 7;24(1):132
pubmed: 32264937
Biomark Med. 2019 Nov;13(16):1373-1386
pubmed: 31617736
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Immun Inflamm Dis. 2020 Mar;8(1):106-123
pubmed: 32031762
Intensive Care Med. 2021 Jan;47(1):119-121
pubmed: 33021683
Intensive Care Med. 2020 Sep;46(9):1787-1789
pubmed: 32661615